Hematologic disorders associated with hepatitis C virus infection and their management.
about
Thrombin activation and liver inflammation in advanced hepatitis C virus infectionBenign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus InfectionTherapeutic issues in HIV/HCV-coinfected patientsHIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders DoPlatelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies.Individualisation of antiviral therapy for chronic hepatitis C.Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitisPeripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy.Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage.Definition and management of anemia in patients infected with hepatitis C virus.Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.Effects of Nigella sativa on outcome of hepatitis C in Egypt.Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsTracking TCRβ Sequence Clonotype Expansions during Antiviral Therapy Using High-Throughput Sequencing of the Hypervariable Region.Successful treatment of myelodysplastic syndrome and chronic hepatitis C using combined peginterferon-α-2b and ribavirin therapy.Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C.Acute septic shock during pegylated-interferon and ribavirin therapy in a patient with chronic hepatitis C who underwent aortic graft replacement.Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients.Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.Ribavirin-associated hemoglobinuria with treatment of hepatitis C virus infection.Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.Treatment Related Hematologic Changes in a Population of Iranian Patients with Chronic Hepatitis C Infection from 2009 to 2014.Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.
P2860
Q26749460-2ADD64FA-8208-4542-9970-6E02B3D6CFF9Q26775733-FAFEB2DB-4FDB-4E0C-813B-62660D5DF496Q27481053-998A2D8A-2A79-42B9-93D4-48E40F0E6BA6Q27491342-FC360AE8-1B07-4673-8B3E-910C0BAD6B37Q33376028-DA75F67F-7801-4EF8-87D9-940EE7AE5E89Q33390478-BF2310F9-DDE8-4CF1-9366-F35187A8EC05Q33394544-E3E8AEE2-70DF-43A3-8944-50016E344724Q33400529-1B4F3BC6-B85B-426B-8F92-910975BEF8D1Q33419462-DD06687E-4603-4B69-8893-E5E5E455C610Q33869261-970560ED-DB2D-4284-911A-945DC433B5EFQ36455842-4203DE60-9A41-459D-8C3B-4E040911E521Q36735210-4ED6A4FF-BAC4-4086-B0AF-9E9DEC9E8EDFQ36821645-8BB36B87-BDE6-403C-B06A-F9D9C56578ECQ36843554-9CA7D50F-D224-43D3-B8AC-D52C445357C8Q38879313-6E3AE969-978A-4428-8C07-E10FCD35BC29Q39316000-24E4CE6C-0E02-40B8-96B5-5B7C8D88D60BQ39325002-AD9D33F9-9FEC-4080-B5CE-A0ACF743D4B6Q40196672-ED074550-073F-4FD7-8D7E-887F68A69C3DQ40323286-A8055A42-E4A7-4FEE-B16A-BD21616948F9Q41497115-857CBE4F-FC03-4B22-B016-02923083F434Q41860936-B9AA764C-576F-40A8-A360-5A3F87BAD0E0Q42205038-4EC438B2-E6AF-4190-B5B1-116752A49CF5Q42983989-3A072DB3-ECCE-49E4-B590-9E744C31D6A8Q43001526-C46C4DAF-734A-472E-A6E0-44A47643A723Q43041256-08126972-7E18-4FBC-B566-2CED7C89F786Q47199643-3CAEC12A-BBFD-4A34-885D-DAEA8E29518AQ50574786-BA7C6981-C4BF-4202-83F6-9241CE0B65E6Q50575347-E69E1A50-EA30-44D8-AB6D-06AC50AAFD48Q50579191-F290CC47-50B3-4D3C-9B1D-6C5CE85F4B09Q50579946-8E62124F-64B6-4C7C-B7A1-3A8C6ED4E77C
P2860
Hematologic disorders associated with hepatitis C virus infection and their management.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Hematologic disorders associated with hepatitis C virus infection and their management.
@ast
Hematologic disorders associated with hepatitis C virus infection and their management.
@en
type
label
Hematologic disorders associated with hepatitis C virus infection and their management.
@ast
Hematologic disorders associated with hepatitis C virus infection and their management.
@en
prefLabel
Hematologic disorders associated with hepatitis C virus infection and their management.
@ast
Hematologic disorders associated with hepatitis C virus infection and their management.
@en
P2860
P356
P1476
Hematologic disorders associated with hepatitis C virus infection and their management.
@en
P2093
Douglas T Dieterich
Jerry L Spivak
P2860
P304
P356
10.1086/376971
P407
P577
2003-08-01T00:00:00Z